Switching among biologic therapies is common practice in patients with rheumatoid arthritis who have an inadequate response or intolerable adverse events. Evidence from observational studies and ...

Tolerability challenges have been identified with tumor necrosis factor (TNF) antagonist therapy in the treatment of rheumatoid arthritis ... including both non-biologic DMARDs such as MTX ...

Rheumatoid arthritis (RA) is a chronic autoimmune condition that affects millions worldwide. According to the World Health Orgnization, 18 million people worldwide were living with the condition in ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...